ISTA Pharmaceuticals Inc.

The Irvine developer of products for treating eye disease, which went public in August, reported a pro forma net loss of $5.6 million, or 36 cents a share, for the fourth quarter, compared with a pro forma net loss of $5.3 million, or 70 cents a share, for the 1999 fourth quarter. A pro forma net loss of $41.1 million, or $3.36 a share, was reported for the year, compared with a pro forma net loss of $14.3 million, or $1.95 a share, for the prior year. No revenue was reported.